Thymosin Alpha-1 Protocol Guide
Thymosin Alpha-1 (Thymalfasin) is a naturally occurring 28-amino-acid peptide produced by the thymus gland that plays a critical role in adaptive immune regulation. Approved in over 35 countries under the brand name Zadaxin for hepatitis B, hepatitis C, and as a vaccine adjuvant, it is one of the most clinically validated peptides available. It enhances T-cell maturation and differentiation, activates dendritic cells and NK cells via TLR2/TLR9 signaling, and shifts cytokine balance toward protective Th1 immunity. This protocol covers reconstitution from a 3mg vial with 1mL bacteriostatic water, subcutaneous dosing at 1.6mg twice weekly, immune enhancement timeline, and stacking with other immune compounds.
Protocol Overview
- Compound
- Thymosin Alpha-1 (N-hexanoyl-Tyr-Ile-(6)-aminohexanoic amide)
- Category
- Immune Modulator / Thymic Peptide
- Mechanism
- Enhances T-cell maturation, activates dendritic cells and NK cells via TLR2/TLR9, promotes Th1 cytokine response
- Structure
- 28 amino acids, acetylated N-terminus
- Half-Life
- ~2 hours
- Vial Size
- 3mg lyophilized powder
- Route
- Subcutaneous injection
- Frequency
- Twice weekly (Mon/Thu)
- Cycle Length
- 8-12 weeks
Dosing Protocol
| Protocol | Dose | Frequency | Route | Duration |
|---|---|---|---|---|
| Standard Nootropic | 50 mcg | 1x daily (AM) | Subcutaneous | 4-8 weeks |
| Conservative Start | 25 mcg | 1x daily (AM) | Subcutaneous | 1-2 weeks, then assess |
| Research Maximum | 100 mcg | 1x daily (AM) | Subcutaneous | 4 weeks maximum |
Key principle: Thymosin Alpha-1 is extremely potent at very low doses. Start with the lowest possible dose and increase only as needed. More is NOT better with this compound due to its exceptional potency at the HGF receptor.
Reconstitution Instructions
Materials Needed
- Thymosin Alpha-1 10mg lyophilized vial
- Bacteriostatic water (2mL)
- 3mL mixing syringe (18-20ga)
- Insulin syringes (29-31ga) for dosing
- Alcohol swabs
Reconstitution Steps
- Clean vial stopper with alcohol
- Draw 2mL bacteriostatic water
- Inject slowly down the vial wall
- Gently swirl (never shake)
- Wait 5 minutes for full dissolution
- Concentration: 5,000 mcg/mL
| Dose | Volume (2mL recon) | Insulin Syringe |
|---|---|---|
| 25 mcg | 0.005 mL | 0.5 units |
| 50 mcg | 0.01 mL | 1 unit |
| 100 mcg | 0.02 mL | 2 units |
| 200 mcg | 0.04 mL | 4 units |
| 500 mcg | 0.10 mL | 10 units |
Administration Guide
Injection Sites
- Abdomen: Primary site, subcutaneous
- Thigh: Outer thigh, alternate sides
- Upper arm: Back of arm, alternate
Timing & Storage
- Timing: Morning administration for cognitive effects during the day
- Vial duration: ~200 days at 50mcg/day
- Storage (reconstituted): Refrigerate 2-8°C, use within 30 days
- Do not freeze reconstituted solution
Expected Timeline
Side Effects & Monitoring
Common Side Effects
- Injection site irritation (mild)
- Vivid dreams (commonly reported)
- Mild headache during initial days
- Increased mental stimulation/difficulty sleeping if dosed late
Limited safety data exists. Thymosin Alpha-1 is a research compound with no human clinical trials completed. Exercise caution with dosing.
Precautions
- No human clinical trial data - preclinical only
- HGF/c-Met activation may theoretically promote tumor growth in predisposed individuals
- Avoid if history of cancer
- Extreme potency requires precise dosing - errors carry higher risk
- Not recommended during pregnancy or breastfeeding
Stacking Recommendations
Compatible Compounds
- Semax: Complementary nootropic via BDNF pathway
- Selank: Anxiolytic support during cognitive enhancement
- NAD+: Cellular energy for neuronal metabolism
- Cerebrolysin: Neurotrophic factor support
- GHK-Cu: Neuroprotective gene expression
Popular Stacks
- Cognitive Stack: Thymosin Alpha-1 50mcg/day + Semax 600mcg/day
- Neuroprotective: Thymosin Alpha-1 + NAD+ + Cerebrolysin
- Full Nootropic: Thymosin Alpha-1 + Semax + Selank
Blood Work Recommendations
| Panel | Markers | Timing |
|---|---|---|
| Basic Panel | CBC, CMP | Baseline, Week 4 |
| Liver Function | ALT, AST, GGT | Baseline, Week 4 |
| Kidney | BUN, creatinine, eGFR | Baseline, Week 4 |
| Inflammatory | CRP, homocysteine | Baseline |
Monitoring is primarily precautionary given the limited human safety data. Track liver and kidney markers to ensure no organ stress from the compound.
Related Tools & Resources
